A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy

Conditions:   HNSCC;   Head and Neck Neoplasms
Intervention:   Drug: Abemaciclib
Sponsor:   Seoul National University Hospital
Recruiting

http://ift.tt/2jv56UV